You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent HNSCC

Showing 1 - 25 of 8,075
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Boston, Massachusetts
  • +1 more
Feb 11, 2023

HNSCC Trial (Danvatirsen, Pembrolizumab)

Not yet recruiting
  • HNSCC
  • (no location specified)
Apr 3, 2023

Metastatic Head Neck Cancer, Recurrent Head Neck Cancer Trial in Worldwide (Bempegaldesleukin, Pembrolizumab)

Terminated
Has Results
  • Metastatic Head and Neck Cancer
  • Recurrent Head and Neck Cancer
  • Omaha, Nebraska
  • +3 more
Dec 16, 2022

Head Neck Cancer Trial in Cincinnati, Columbus (Niraparib, Dostarlimab)

Active, not recruiting
  • Head and Neck Cancer
  • Cincinnati, Ohio
    University of Cincinnati Medical Center
Jan 31, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Cancer Trial in United States (IK-175 + nivolumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +5 more
  • IK-175 + nivolumab
  • Chicago, Illinois
  • +3 more
Jul 26, 2022

Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)

Not yet recruiting
  • Head and Neck Cancer
  • +3 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023

Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Dec 20, 2022

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Head and Neck Squamous Cell Carcinoma Trial in Candiolo (inulin, Pembrolizumab, Nivolumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • inulin
  • +2 more
  • Candiolo, Turin, Italy
    Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Apr 7, 2023

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Head Neck Cancer Trial in Tyler (Buparlisib & Paclitaxel)

Recruiting
  • Head and Neck Cancer
  • Buparlisib & Paclitaxel
  • Tyler, Texas
    Hope Cancer Center, UT Health East Texas
Aug 11, 2022

HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)

Not yet recruiting
  • HPV-Related Squamous Cell Carcinoma
  • HNSCC
  • London, United Kingdom
    East and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Dalpiciclib+cetuximab)

Recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Feb 9, 2023

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

HNSCC Trial in Worldwide (Eftilagimod alpha, Pembrolizumab)

Recruiting
  • HNSCC
  • Birmingham, Alabama
  • +28 more
Nov 29, 2022

Head and Neck Squamous Cell Carcinoma Trial (pembrolizumab)

Completed
Has Results
  • Head and Neck Squamous Cell Carcinoma
  • pembrolizumab
  • (no location specified)
Jun 23, 2022

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease Trial in New York (OBP-301,

Terminated
  • Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
  • New York, New York
    Weill Cornell Medicine
Jul 6, 2022

HNSCC Trial in Houston (Bimiralisib)

Terminated
Has Results
  • HNSCC
  • Houston, Texas
    M.D. Anderson Cancer Center
Dec 22, 2021

Head and Neck Tumors Trial in France (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Head and Neck Neoplasms
  • Lyon, France
  • +6 more
May 16, 2022

Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Seoul (Nivolumab)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Seoul, Korea, Republic of
    Yonsei Severance Hospital
Jan 27, 2022

HNSCC Trial in United States (Tipifarnib, Alpelisib)

Recruiting
  • HNSCC
  • Duarte, California
  • +10 more
Jun 30, 2022

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (SI-B001, Paclitaxel)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Shanghai Oriental Hospital
Mar 3, 2022